<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01872390</url>
  </required_header>
  <id_info>
    <org_study_id>AAAK7103</org_study_id>
    <secondary_id>AID-OAA-A-12-00022</secondary_id>
    <nct_id>NCT01872390</nct_id>
  </id_info>
  <brief_title>Start TB Patients on ART and Retain on Treatment (START Study)</brief_title>
  <acronym>START</acronym>
  <official_title>Start TB Patients on ART and Retain on Treatment: Combination Intervention Package to Enhance Antiretroviral Therapy Uptake and Retention During TB Treatment in Lesotho</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the START Study is to identify an effective, cost-effective, acceptable
      intervention that addresses programmatic, structural and psychosocial barriers to ART
      initiation and retention during TB treatment, with the ultimate goal of improving health
      outcomes among HIV-infected TB patients in Lesotho. The study is a two-arm cluster randomized
      trial, randomized at the TB/HIV clinic level, which includes twelve TB/HIV clinics in Berea
      district. Clinics are randomized to deliver the combination intervention package (CIP) or
      standard of care (SOC), with stratification by facility type. The experimental intervention
      will be delivered to all HIV-infected TB patients in TB/HIV clinics randomly assigned to CIP.
      In TB/HIV clinics assigned to SOC, usual care procedures for ART initiation and retention
      will be delivered.

      Study hypotheses focus on the effectiveness of the CIP on HIV- and TB-related outcomes.

      Compared to HIV-infected TB patients attending SOC clinics, HIV-infected TB patients at CIP
      clinics will have superior HIV- and TB-related outcomes, including:

        -  Greater ART initiation during TB treatment

        -  Shorter time to ART initiation

        -  Greater retention in ART care

        -  Higher adherence to ART

        -  Greater change in CD4+ count

        -  Greater TB treatment success (completion and cure)

        -  Greater sputum smear conversion

        -  Higher adherence to TB treatment

      Additionally, CIP delivery will have an incremental cost-effectiveness ratio more favorable
      than alternative resource uses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among people living with HIV (PLWH), tuberculosis (TB) is the most common opportunistic
      illness and a leading cause of death, accounting for nearly a quarter of HIV-related deaths
      worldwide. Initiating antiretroviral therapy (ART) early during TB treatment significantly
      increases survival, and World Health Organization (WHO) guidelines recommend ART initiation
      for all PLWH as soon as possible after TB treatment initiation, regardless of CD4+ count. Yet
      in the African Region, only 42% of TB patients known to be living with HIV were on ART in
      2010, and retention in ART programs has been limited. In Lesotho, only 27% of HIVinfected TB
      patients received ART in 2010. There is an urgent need to identify programmatic interventions
      that increase the proportion of HIV-infected TB patients on ART, shorten the duration between
      TB diagnosis and ART initiation, and improve adherence to medications and retention in care
      amongst HIV-infected TB patients in Lesotho.

      Lesotho, a small, landlocked country completely surrounded by South Africa, is among the
      world's poorest nations with one of the world's most severe epidemics of HIV and tuberculosis
      (TB). There is strong evidence that TB patients who are also infected with HIV have better
      survival rates if they begin antiretroviral therapy (ART) soon after starting TB treatment;
      however, there are many patients who do not initiate ART within the recommended timeframe,
      and who do not remain in care.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of TB/HIV patients newly registered during period of observation who initiate ART during TB treatment</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>To examine ART initiation based on review of clinic registers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who attended 6 month clinic visit (within 1 month window) and reported ART use</measure>
    <time_frame>Up to 6 months after TB treatment initiation</time_frame>
    <description>To examine ART retention. Deaths and transfers will be considered not retained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with cure + treatment completion at end of TB treatment</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>To examine TB treatment success as defined by WHO, based on review of TB register and treatment cards.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days from TB treatment initiation to date of ART initiation</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>To examine Time to ART initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of total prescribed doses ingested for ART</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>To examine ART adherence, averaged across medicines for each month of treatment, from the unannounced pill counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ count</measure>
    <time_frame>Up to 6 months after initial CD4 count</time_frame>
    <description>To examine change in CD4 count over 6 months (from initiation of TB treatment to 6 months later). Routine clinical CD4 test results will be used by study staff and no additional blood draw will be required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of smear positive pulmonary TB cases that converted to smear negative after eight weeks of treatment</measure>
    <time_frame>Up to 8 weeks from initiation of TB treatment</time_frame>
    <description>To examine sputum smear conversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of total prescribed doses ingested for TB treatment</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>To examine TB treatment adherence, from unannounced pill counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of the incremental costs of the CIP to incremental effectiveness</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>To examine incremental cost-effectiveness of CIP (per ART initiation, retention, and TB treatment completion)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">415</enrollment>
  <condition>Tuberculosis</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>CIP Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients, and in addition the Combination Intervention Package (CIP) with the programmatic, structural, and psychosocial components.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC Participants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients. TB and HIV services are fully integrated in a one-stop model, while at hospitals, ART is provided in the TB clinic for TB/HIV coinfected patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Combination Intervention Package</intervention_name>
    <description>CIP will contain programmatic, structural and psychosocial components including: 1) nurse training and mentorship in TB/HIV cotreatment using a clinical algorithm; 2) reimbursement of transportation costs to monthly clinic visits for patients and treatment supporters; 3) health education using a TB and HIV treatment literacy curriculum for patients and treatment supporters; and 4) real-time adherence support using short message service (SMS) text messaging and trained village health workers (VHW). These components were selected for their promise, practicality, and feasibility of implementation and scale-up in HIV programs in diverse settings - in addition to SOC.</description>
    <arm_group_label>CIP Participants</arm_group_label>
    <other_name>CIP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Usual procedures for management of HIV-infected TB patients will be followed: Three I's training, ART provision to TB patients in integrated clinics, and treatment supporter for TB treatment.</description>
    <arm_group_label>SOC Participants</arm_group_label>
    <other_name>SOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Measurement Cohort Participant Inclusion Criteria:

          1. HIV-infected

          2. On TB treatment

          3. Initiating ART within 2 months of TB treatment initiation

          4. Aged 18 or older

          5. English- or Sesotho-speaking

          6. Capable of informed consent

        Measurement Cohort Participant Exclusion Criteria:

          1. Children under age of 18

          2. Patients diagnosed with Multi Drug Resistant-TB (MDR-TB)

        Key Informats: Three groups of key informats (KI) will be recruited.

          -  Key Informants ART Early-Initiators Inclusion Criteria:

               1. A measurement cohort participant

               2. Initiaing ART within the first 8 weeks of TB treatment

          -  Key Informants ART Non/Late-Initiators Inclusion Criteria:

               1. A measurement cohort participant

               2. did not initiate ART during TB treatment or initiating ART &gt;= 2 months after TB
                  treatment initiation

          -  Key Informants Healthcare Workers Inclusion Criteria:

               1. Nurse or VHW working in a CIP clinic or VHW working in the community and
                  affiliated with CIP clinic

               2. Aged 18 or older

               3. English- or Sesotho‚Äêspeaking

               4. Capable informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea A Howard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Berea Hospital</name>
      <address>
        <city>Berea</city>
        <state>Berea District</state>
        <country>Lesotho</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Shepherd Health Center</name>
      <address>
        <city>Berea</city>
        <state>Berea District</state>
        <country>Lesotho</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Family Health Center</name>
      <address>
        <city>Berea</city>
        <state>Berea District</state>
        <country>Lesotho</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khubetsoana Health Center</name>
      <address>
        <city>Berea</city>
        <state>Berea District</state>
        <country>Lesotho</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koali Health Center</name>
      <address>
        <city>Berea</city>
        <state>Berea District</state>
        <country>Lesotho</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kolojane Health Center</name>
      <address>
        <city>Berea</city>
        <state>Berea District</state>
        <country>Lesotho</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maluti Hospital</name>
      <address>
        <city>Berea</city>
        <state>Berea District</state>
        <country>Lesotho</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pilot Health Center</name>
      <address>
        <city>Berea</city>
        <state>Berea District</state>
        <country>Lesotho</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sebedia Health Center</name>
      <address>
        <city>Berea</city>
        <state>Berea District</state>
        <country>Lesotho</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Magdalena Health Center</name>
      <address>
        <city>Berea</city>
        <state>Berea District</state>
        <country>Lesotho</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. David Health Center</name>
      <address>
        <city>Berea</city>
        <state>Berea District</state>
        <country>Lesotho</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Theresa Health Center</name>
      <address>
        <city>Berea</city>
        <state>Berea District</state>
        <country>Lesotho</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lesotho</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Andrea Howard</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Epidemiology (in ICAP)</investigator_title>
  </responsible_party>
  <keyword>Lesotho</keyword>
  <keyword>TB</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>HIV</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>ART</keyword>
  <keyword>adherence</keyword>
  <keyword>combination intervention package</keyword>
  <keyword>retention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

